K A Phillips
Affiliation: University of Melbourne
- Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?K A Phillips
Samuel Lunenfeld Research Institute and Marvelle Koffler Breast Center, Mt Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada
J Clin Oncol 17:3653-63. 1999..To review the preclinical and clinical studies relevant to the prognosis and prognostic associations of BRCA1- and BRCA2-associated breast carcinomas, with an emphasis on research methodology...
- Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2K A Phillips
Department of Medical Oncology and Haematology, Princess Margaret Hospital, Toronto, Ontario, Canada
Clin Genet 57:376-83. 2000..The focus on altruistic factors and those related to perceived psychological benefits of testing is notable...
- Breast conservation in BRCA1 or BRCA2 mutation carriers with early stage breast cancerK A Phillips
Department of Haematology, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
Australas Radiol 45:200-4. 2001..Further, methodologically rigorous studies of large numbers of breast cancer patients who carry a mutation in BRCA1 or BRCA2 are required to fully elucidate these issues...
- Current perspectives on BRCA1- and BRCA2-associated breast cancersK A Phillips
Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
Intern Med J 31:349-56. 2001....
- Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort studyK A Phillips
Division of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne Department of Medicine, St Vincent s Hospital, Victoria, NSW, Australia
Clin Genet 70:198-206. 2006..In this cohort, the minority of mutation carriers utilized risk-reducing surgery or chemoprevention and a substantial minority were not undergoing regular cancer-screening tests...
- Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancerB E Kiely
Division of Cancer Medicine, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Melbourne, Vic, 8006, Australia
Fam Cancer 10:505-14. 2011..Additional education of clinicians and consumers is needed to ensure optimal surgery and pathology in these women...
- Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive familiesS L Harvey
Division of Cancer Medicine, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Melbourne, VIC 8006, Australia
Breast Cancer Res Treat 130:1057-61. 2011..Despite this being the largest prospective cohort to assess this issue, moderately increased breast cancer risk (2-fold) cannot be ruled out...
- Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomyC I Scott
Department of Hematology and Medical Oncology, Familial Cancer Center, Peter MacCallum Cancer Institute, St Andrew s Place, East Melbourne, Victoria, 3002, Australia
Clin Genet 64:111-21. 2003....
- Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancersK A Phillips
Peter MacCallum Cancer Institute, Victoria, Australia
J Clin Oncol 18:107S-12S. 2000....
- Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentreR J MacInnis
1 Cancer Epidemiology Centre, Cancer Council Victoria, Victoria, Melbourne, Australia 2 Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Victoria, Melbourne, Australia
Br J Cancer 109:1296-301. 2013..70 (95% CI 0.66-0.75) and there was no evidence of systematic under- or over-dispersion (P=0.2).Conclusion:BOADICEA is well calibrated for Australian women, and had good discrimination and accuracy at the individual level. ..
- Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancerK M Field
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag No 1, A Beckett St, Melbourne, Victoria 8006, Australia
Eur J Cancer 45:551-60. 2009..Few data exist regarding the use of complementary and alternative medicine (CAM) by unaffected women at high risk of breast cancer...
- Morphological predictors of BRCA1 germline mutations in young women with breast cancerM C Southey
Department of Pathology, Genetic Epidemiology Laboratory, Victoria, Carlton, Australia
Br J Cancer 104:903-9. 2011..We sought an optimal strategy for identifying carriers using family history, breast cancer morphology and hormone receptor status data...